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Abstract
Purpose Little is known about the actual involvement of
the general practitioner (GP) during the active breast cancer
treatment phase. Therefore, this study explored (disease-
specific) primary health care use among women undergoing
active treatment for breast cancer compared with women
without breast cancer.
Methods A total of185 women witha first diagnosis ofearly-
stage breast cancer between 1998 and 2007 were identified in
the primary care database of the Registration Network
Groningen and matched with a reference population of 548
women without breast cancer on birth year and GP.
Results Since diagnosis, patients with breast cancer had
twice as many face-to-face contacts compared with women
from the reference population (median 6.0 vs 3.0/year,
Mann–Whitney (M-W) test p<0.001). The median number
of drug prescriptions and referrals was also significantly
higher among patients than among the reference population
(11.0 vs 7.0/year, M-W test p<0.001 and 1.0 vs 0.0/year,
M-W test p<0.001). More patients than women from the
reference population had face-to-face contacts or were
prescribed drugs for reasons related to breast cancer and
its treatment, including gastrointestinal problems, psycho-
logical reasons and endocrine therapy.
Conclusions During the active breast cancer treatment
phase, GPs are involved in the management of treatment-
related side effects and psychological symptoms, as well as
in the administration of endocrine therapy. Based on the
findings of this study, interventions across the primary/
secondary interface can be planned to improve quality of
life and other outcomes in patients undergoing breast
cancer treatment.
Keywords Breast cancer.Health care utilisation.General
practice.Active treatment phase.Primary care database
Introduction
Little is known about the actual involvement of the general
practitioner (GP) in care for patients undergoing treatment
for breast cancer. Traditionally, GPs have had a major role
in early detection of cancer [1–3] and in symptom control
during the palliative cancer stage [1, 2]. In Europe and
North America, there is a now an explicit recognition that
GPs and other primary care physicians should be involved
in all stages of cancer care [1–5] and that they are players
on the same team as oncologists [6–8].
Surgical treatment and systemic therapies can have a
major impact on patients’ lives. For example, patients may
experience psychosocial distress and treatment-related side
effects that negatively affect their health-related quality of
life and adherence to adjuvant therapies [9–11]. A better
understanding of the role of the GP during the active breast
cancer treatment phase is important for coordination of care
across the primary/secondary interface to improve these and
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treatment [2, 3, 5, 12, 13].
A British study showed that women with early breast
cancer consulted their GP more often in the year after
diagnosis than in the year before diagnosis [14], but
primary care consultations were not compared between
women with and without breast cancer. In another study
among Canadian patients with (breast) cancer, contact rates
with GPs and family physicians increased compared to
baseline (pre-diagnosis), during the peri-diagnostic and
active treatment periods [15]. However, it remains unclear
for what reasons patients with breast cancer do consult their
primary care physician. The objectives of the current study
were (1) to explore (disease-specific) primary health care
use among women undergoing treatment for breast cancer
compared with women without breast cancer and (2) to




An analysis of health care use was conducted using the
database of the Registration Network Groningen (RNG).
This general practice research network was established in
1989 and consists of three group practices with 17 GPs and
a dynamic population of approximately 30,000 patients in
the city of Groningen and the smaller towns Hoogeveen
and Sappemeer in the northern part of the Netherlands.
According to the privacy instructions given by the RNG,
anonymized patient records were used in data collection
and data analysis. No further approval from the Institutional
Review Board of the University Medical Centre Groningen
was needed because the study was in agreement with the
regulations for publication of patient data.
Participants and data collection
A total of 422 women with a recorded code for female
breast malignancy in at least one of five files in their patient
record (worksheet, episodes, prescriptions, referrals and
problem list) between 1998 and 2007 were identified in the
RNG database. Confirmation of breast cancer in history
was obtained for 400 patients by going back to participating
general practices and examining electronic records, elec-
tronic specialist letters and paper records (when available)
[16]. Additional information about breast cancer diagnosis,
stages, treatments and recurrences was also collected for
these patients. Specialist letters were found for 312 patients
(78.0%). The first date when the recorded code for female
breast malignancy was entered into the patient record was
not taken as the date of diagnosis, since the actual diagnosis
will be made in the hospital and will usually later be
recorded by GPs [17]. In 326 patients (81.5%), date of first
recording of breast symptoms/breast cancer in worksheet
and/or date of first referral letter was taken as the date of
breast cancer diagnosis, while in 74 patients (18.5%), date
of first hospital visit, date of specialist letter after first
hospital visit or first date of breast cancer surgery was taken
as the date of breast cancer diagnosis. The number of
patients with a first diagnosis of early-stage breast cancer
between 1998 and 2007 and registered with a participating
GP at time of diagnosis determined the study size. Patients
with a first breast cancer diagnosis before 1998 (n=181),
patients with distant metastasis at diagnosis (n=10) and
patients who were not registered with a participating GP at
diagnosis (n=21) were excluded from the study (Fig. 1).
A reference population was identified from the entire
female population in the RNG database, not including
Fig. 1 Flow diagram of the identification and inclusion of patients
with early-stage breast cancer
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(n=188) were individually matched with three women
from the reference population on birth year (±1 year) and
GP, to control for age [18] and variation in recording
diagnoses and prescribing drugs among GPs. Women from
the reference population were eligible if they were
registered with the same GP as the corresponding patient
at breast cancer diagnosis. Three patients could not be
matched and were excluded, leaving 185 patients and 548
women from the reference population for data analysis
(Fig. 1). For each of the 180 patients (97.3%), 3 women
from the reference population who met the matching
criteria could be identified. At least one woman from the
reference population was identified for each of the
remaining five patients (2.7%). For patients and reference
population, data collected by the RNG between 1998 and
2007 were entered into an anonymous database and
included patient contacts recorded by participating GPs
using the International Classification of Primary Care (ICPC)
version 1 [19], prescribed medication automatically classified
according to the Anatomical Therapeutical Chemical (ATC)
classification [20] and referrals.
Data analysis
To study the active breast cancer treatment phase, we
calculated health care utilisation rates in the year since
diagnosis compared with these rates in the year before
diagnosis. However, utilisation rates in general practice are
not only affected by the chosen study period (1998–2007)
Patients Ref. pop. p value
General practice, n (%) 0.926
a
Groningen 64 (34.6) 182 (33.2)
Hoogeveen 55 (29.7) 170 (31.0)
Sappemeer 66 (35.7) 196 (35.8)
Age at diagnosis, median (range), years 56.2 (27.4–96.0) 55.8 (26.8–94.8) 0.854
b
















c + radiation therapy 26 (14.1)
Systemic treatment, n (%)
None 85 (45.9)
Chemotherapy 20 (10.8)
Endocrine therapy 36 (19.5)
Chemotherapy + endocrine therapy 44 (23.8)
Early endpoints in year since diagnosis, n (%)
Recurrent breast cancer 1 (0.5)
Departure 3 (1.6) 10 (1.8)
Death 1 (0.5) 11 (2.0)
Other 0 (0.0) 3 (0.5)
Observation time, median (range), days
Period before diagnosis 365.0 (4.0–366.0) 365.0 (4.0–366.0) 0.716
b
Period since diagnosis 365.0 (33.0–366.0) 365.0 (10.0–366.0) 0.922
b
Table 1 Characteristics of
women with early-stage breast
cancer (n=185) and women




cIncluding patients treated with
lumpectomy followed by mastec-
tomy
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practice, and death. Therefore, 30 patients and 83 women
from the reference population have a shorter observation
time before diagnosis (<365 days) due to time of entry in
general practice. In addition, four patients have a shorter
observation time since diagnosis (<365 days) because of
recurrent breast cancer (n=1), departure (n=3) and death
(n=1). The same is true for 24 women from the reference
population, due to departure (n=10), death (n=11) and
other (unknown) reasons (n=3). Nevertheless, median
observation time is not statistically different between both
groups (Table 1). Annual health care utilisation rates were
calculated by dividing the number of face-to-face contacts,
drug prescriptions and referrals in a period by the
observation time in that period (Table 2). Face-to-face
contacts included consultations in general practice as well
as home visits in the patient’s home, carried out by GPs
and other general practice workers. Frequencies of face-to-
face contacts, drug prescriptions and referrals per year and
per month were calculated (Table 2 and Fig. 2), as well as
frequencies of face-to-face contacts and drug prescriptions
for specific reasons based on ICPC chapters, ATC chapters
and the three to seven digit ATC codes. Frequencies of
face-to-face contacts were only divided by subgroups
based on ICPC chapters, due to small numbers when using
three digits ICPC codes. An exception was made for
breast symptoms and breast cancer (Table 3).
Database management was performed in Microsoft
Access 2003. For analysis, data were transferred to SPSS
version 16. Non-parametric tests and logistic regression
models were used due to the skewed distribution of the
data. Differences in characteristics of women with breast
cancer and women from the reference population were
analysed with the Chi-square (χ
2) test and Mann–Whitney
(M-W) test (Table 1). The Wilcoxon signed-rank test and
McNemar test were conducted to explore change in rates
and frequencies within patients (Table 2), while the M-W
test and χ
2 test were used to compare differences in rates
and frequencies between patients and women from the
reference population in the period since diagnosis (Tables 2
and 3). Furthermore, univariate logistic regression analysis
was used to evaluate if annual face-to-face contact rates and
drug prescription rates in the period before diagnosis and
certain patient characteristics were associated with face-to-
face contact rates and drug prescription rates in the period
since diagnosis. Multivariate logistic regression analysis
was then performed to evaluate patient characteristics that
were significantly related to drug prescription rates in
univariate analysis (p<0.01). Only the main effects were
tested in the model due to the small number of patients
(Table 4).
Results
Characteristics of women with early-stage breast cancer
(n=185) and women from the reference population (n=548)
are presented in Table 1. There were no significant differ-
ences between the two groups in general practice, age at
diagnosis and amount of observation time in the periods
before and since breast cancer diagnosis. Median age at
diagnosis among patients was 56.2 (range 27.4–96.0) years.
Table 2 Annualhealthcareutilisationratesbeforeandsincebreastcancer diagnosisas wellasfrequenciesofwomenwithanyface-to-facecontact,any
drug prescription and any referral in both periods among women with breast cancer (n=185) and women from the reference population (n=548)
Annual health care utilisation
Before diagnosis Since diagnosis
Patients Ref. pop. Patients Ref. pop.
Face-to-face contacts
Median (range) 2.2 (0.0–18.7) 2.0 (0.0–32.0) 6.0 (0.0–46.0) 3.0 (0.0–31.7)
Women with any face-to-face contact, n (%) 149 (80.5) 428 (78.1) 184 (99.5) 428 (78.1)
Drug prescriptions
Median (range) 6.0 (0.0–220.0) 6.0 (0.0–111.0) 11.0 (0.0–212.0) 7.0 (0–127.0)
Women with any drug prescription, n (%) 156 (84.3) 437 (79.7) 170 (91.9) 447 (81.6)
Referrals
Median (range) 0.0 (0.0–13.8) 0.0 (0.0–6.9) 1.0 (0.0–11.1) 0.0 (0.0–7.9)
Women with any referral, n (%) 53 (28.6) 157 (28.6) 165 (89.2) 164 (29.9)
All changes in utilisation rates and frequencies within patients are significant (Wilcoxon signed-rank test, p<0.001 and McNemar Test, p<0.01),
as well as all differences in utilisation rates and frequencies in the year since diagnosis between patients and reference population (Mann–Whitney
test, p<0.001 and Chi-square test, p<0.01)
708 Support Care Cancer (2012) 20:705–714T stage and N stage were known for 174 patients (94.1%)
and 179 patients (96.8%), respectively. Among 112 patients
(60.5%), breast cancer was detected without regional lymph
nodes involved. A total of 93 patients (53.0%) underwent
lumpectomy and radiation therapy, while 100 patients
(54.1%) received systemic treatment. One patient presented
with recurrent breast cancer (distant metastasis) during the
first year since breast cancer diagnosis.
Table 2 gives annual health care utilisation rates in the
periods before and since breast cancer diagnosis as well as
frequencies of women with any face-to-face contact, any drug
prescription and any referral in both periods. Since breast
cancer diagnosis, health care utilisation in general practice
increased significantly among patients, compared to the
period before diagnosis and compared to the reference
population. Patients had twice as many face-to-face contacts
as women from the reference population (median 6.0 vs 3.0/
year, M-W test p< 0 . 0 0 1 ) .T h em e d i a nn u m b e ro fd r u g
prescriptions and referrals was also significantly higher
among patients than among the reference population (11.0
vs 7.0/year, M-W test p<0.001 and 1.0 vs 0.0/year, M-W test
p<0.001). Frequencies of patients with any face-to-face
contact, any drug prescription and any referral also
increased since diagnosis. With respect to referrals, more
patients than women from the reference population were
referred to a surgeon [132 (71.4%) vs 15 (2.7%), χ
2 test
p<0.001] and a physical therapist [27 (14.6%) vs 33 (6.0%),
χ
2 test p<0.001] in this period (data not shown in Table 2).
Timing of health care use in relation to breast cancer
diagnosis is shown in Fig. 2. The percentage of women
with breast cancer with any face-to-face contact, any drug
prescription and any referral per month increased since
breast cancer diagnosis: e.g. in the first month since
diagnosis, 166 patients (89.7%) had any face-to-face
contact, 100 patients (54.1%) were prescribed any drugs,
and 134 patients (72.4%) were referred at least once. The
percentage of patients with any face-to-face contact per
month decreased gradually after the first month since
diagnosis, while the percentage of women with any drug
prescription remained higher among patients than among
women from the reference population. In the first month
since diagnosis, 126 patients (87.6%) were referred to a
surgeon (data not shown in Fig. 2).
Among patients and reference population, 35 (2.6%) and
57 (3.0%) face-to-face contacts, respectively, in the period
since diagnosis could not be linked to any ICPC code.
Table 3 shows that, compared to the reference population,
significantly more patients had face-to-face contacts in the
period following diagnosis for general reasons, blood(-
forming organs) and immune mechanism, psychological
reasons, the skin, breast symptoms and breast cancer. Also,
significantly more patients than women from the reference
population were prescribed drugs for the alimentary tract,
dermatologicals, corticosteroids, anti-infective drugs, endo-
crine therapy, analgesics and psycholeptics. Less patients
than women from the reference population were prescribed
drugs for the genito-urinary system and sex hormones.














































Fig. 2 Timing of health care use in relation to breast cancer diagnosis
among women with breast cancer (n=185) and women from the
reference population (n=548). Percentage of women with any face-to-
face contact, any drug prescription and any referral per month. Note:
time 0 is the first month since date of breast cancer diagnosis
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contact and any drug prescription since breast cancer diagnosis for specific reasons
Since diagnosis
Patients Ref. pop.
Women with any face-to-face contact by ICPC chapter/code, n (%)
General and unspecified (A)*** 62 (33.5) 78 (14.2)
Blood, blood-forming organs and immune mechanism (B)* 13 (7.0) 16 (2.9)
Digestive (D) 40 (21.6) 92 (16.8)
Eye (F) 10 (5.4) 34 (6.2)
Ear (H) 12 (6.5) 51 (9.3)
Cardiovascular (K) 40 (21.6) 142 (25.9)
Musculoskeletal (L) 69 (37.3) 188 (34.3)
Neurological (N) 20 (10.8) 60 (10.9)
Psychological (P)* 34 (18.4) 64 (11.7)
Respiratory (R) 54 (29.2) 121 (22.1)
Skin (S)** 65 (35.1) 135 (24.6)
Endocrine, metabolic and nutritional (T) 18 (9.7) 48 (8.8)
Urological (U) 13 (7.0) 34 (6.2)
Pregnancy, childbearing and family planning (W)
a 1 (0.5) 12 (2.2)
Female genital (X)*** 177 (95.7) 99 (18.1)
Breast symptoms (X18–X21)*** 131 (70.8) 11 (2.0)
Breast cancer (X76)*** 157 (84.9) 0 (0.0)
Social problems (Z) 12 (6.5) 37 (6.8)
Women with any drug prescription by ATC chapter/code, n (%)
Alimentary tract and metabolism (A)*** 94 (50.8) 165 (30.1)
Drugs for functional gastrointestinal disorders (A03)*** 34 (18.4) 16 (2.9)
Propulsives (A03F)*** 31 (16.8) 10 (1.8)
Antiemetics and antinauseants (A04)*** 24 (13.0) 2 (0.4)
Serotonin (5-HT3) antagonists (A04AA)*** 24 (13.0) 2 (0.4)
Laxatives (A06)*** 35 (18.9) 41 (7.5)
Osmotically acting laxatives (A06AD)*** 27 (14.6) 28 (5.1)
Antidiarrheals, intestinal anti-inflammatory/infective agents (A07)*** 16 (8.6) 9 (1.6)
Blood and blood-forming organs (B) 31 (16.8) 77 (14.1)
Cardiovascular system (C) 72 (38.9) 206 (37.6)
Dermatologicals (D)* 55 (29.7) 114 (20.8)
Antibiotics and chemotherapeutics for dermatological use (D06)** 12 (6.5) 13 (2.4)
Genito-urinary system and sex hormones (G)** 17 (9.2) 94 (17.2)
Sex hormones and modulators of the genital system (G03)** 9 (4.9) 79 (14.4)
Hormonal contraceptives for systemic use (G03A)** 3 (1.6) 43 (7.8)
Systemic hormonal preparations, excl. sex hormones and insulins (H)* 32 (17.3) 60 (10.9)
Corticosteroids for systemic use (H02)* 22 (11.9) 34 (6.2)
Corticosteroids for systemic use, plain (H02A)* 22 (11.9) 34 (6.2)
Anti-infectives for systemic use (J)** 98 (53.0) 211 (38.5)
Antibacterials for systemic use (J01)*** 77 (41.6) 134 (24.5)
Beta-lactam antibacterials, penicillins (J01C)*** 35 (18.9) 45 (8.2)
Antineoplastic and immunomodulating agents (L)*** 66 (35.7) 6 (1.1)
Endocrine therapy (L02)*** 65 (35.1) 0 (0.0)
Hormone antagonists and related agents (L02B)*** 64 (34.6) 0 (0.0)
Anti-estrogens (L02BA)*** 53 (28.6) 0 (0.0)
Tamoxifen (L02BA01)*** 53 (28.6) 0 (0.0)
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tact rates and drug prescription rates are summarized in
Table 4. In univariate analysis, a higher face-to-face contact
rate before diagnosis (OR 2.59, 95% CI 1.43–4.70), a
higher T stage (OR 1.93, 95% CI 1.05–3.55), treatment
with mastectomy (OR 1.86, 95% CI 1.03–3.37) and
treatment with endocrine therapy (OR 2.09, 95% CI 1.16–
3.78) were related to a higher face-to-face contact rate since
diagnosis. Patient characteristics associated with a higher
drug prescription rate since diagnosis were a higher drug
prescription rate before diagnosis (OR 22.90, 95% CI
10.67–49.14), general practice (Hoogeveen: OR 2.89, 95%
CI 1.37–6.09) and age at diagnosis (OR 2.70, 95% CI 1.49–
4.89). Multivariate analysis was not performed for face-to-
face contact rates since only a higher face-to-face contact
rate before diagnosis reached a lower p value of 0.01. The
main patient characteristics associated with higher face-to-
face contact rates and drug prescription rates since diagnosis
were higher face-to-face contact rates and drug prescription
rates before diagnosis (OR 2.59, 95% CI 1.43–4.70 and OR
23.23, 95% CI 10.14–53.22).
Discussion
This is the first study to compare (disease-specific) primary
health care use between women undergoing treatment for
breast cancer and women without breast cancer and to
identify specific patient characteristics associated with
primary health care use. In accordance with the two
previous studies, contact rates with GPs increased during
the active breast cancer period when compared to the pre-
diagnostic period [14, 15]. The percentage of women with
any face-to-face contact decreased gradually after the first
month since diagnosis but remained higher among patients
than among the reference population. The increase in the
percentage of patients with at least one drug prescription
also sustained over time. Furthermore, we found that
treatment-related side effects, including nausea and vomit-
ing, constipation, diarrhoea, skin problems, pain and sleep
disturbance, were managed in general practice. Severe side
effects and co-morbidities are associated with less (fre-
quent) use, reduction in dose and breaks and discontinua-
tion of adjuvant therapies [11, 21–25]. Management of
these side effects and co-morbidities is very important for
patients with breast cancer to improve their health-related
quality of life, to complete adjuvant therapies and to
prevent early mortality [2, 9–11]. In our study, women
with breast cancer had more contacts with general practice
for psychological reasons and more prescriptions for
psycholeptics since diagnosis than women without breast
cancer. Although psychological symptoms are often unrec-
ognized [12, 26], there is potential for these symptoms to be
identified and treated in primary care, especially given the
ongoing nature of the patient–doctor relationship and the
easy access to primary care [26]. Our study also showed
that GPs were involved in the administration of endocrine
therapy and that treatment with endocrine therapy is
predictive of a higher face-to-face contact rate in general




Musculoskeletal system (M) 50 (27.0) 145 (26.5)
Nervous system (N)*** 96 (51.9) 203 (37.0)
Analgesics (N02)** 47 (25.4) 80 (14.6)
Other analgesics and antipyretics (N02B)** 31 (16.8) 50 (9.1)
Anilides (N02BE)*** 31 (16.8) 45 (8.2)
Psycholeptics (N05)*** 81 (43.8) 133 (24.3)
Anxiolytics (N05B)*** 62 (33.5) 90 (16.4)
Benzodiazepine derivatives (N05BA)*** 61 (33.0) 88 (16.1)
Hypnotics and sedatives (N05C)*** 37 (20.0) 55 (10.0)
Benzodiazepine derivatives (N05CD)*** 37 (20.0) 53 (9.7)
Antiparasitic products, insecticides and repellents (P)
a 0 (0.0) 0 (0.0)
Respiratory system (R) 54 (29.2) 125 (22.8)
Sensory organs (S) 26 (14.1) 68 (12.4)
Various (V)
a 0 (0.0) 2 (0.4)
Chi-square test, *p<0.05, **p<0.01 and ***p<0.001
aGroups with an expected count of less than five were not tested with the Chi-square test
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Univariate Multivariate
≤ Median > Median OR (CI) OR (CI)
Outcome: annual face-to-face contact rate since diagnosis n=100 n=85
Face-to-face contact rate before diagnosis, n (%)
≤ Median 61 (61.0) 32 (37.6) 1
> Median 39 (39.0) 53 (62.4) 2.59 (1.43–4.70)**
General practice, n (%)
Groningen 41 (41.0) 23 (27.1) 1
Hoogeveen 27 (27.0) 28 (32.9) 1.85 (0.89–3.86)
Sappemeer 32 (32.0) 34 (40.0) 1.89 (0.94–3.82)
Age at diagnosis, n (%)
≤ Median 55 (55.0) 38 (44.7) 1
> Median 45 (45.0) 47 (55.3) 1.51 (0.85–2.70)
T stage, n (%)
Tis/T1 61 (63.5) 37 (47.2) 1
T2/T3/T4 35 (36.5) 41 (52.6) 1.93 (1.05–3.55)*
N stage, n (%)
N0 63 (64.3) 49 (60.5) 1
N+ 35 (35.7) 32 (39.5) 1.18 (0.64–2.16)
Surgery, n (%)
Lumpectomy
a 58 (59.2) 37 (44.0) 1
Mastectomy
b 40 (40.8) 47 (56.0) 1.86 (1.03–3.37)*
Chemotherapy, n (%)
No 65 (65.0) 56 (65.9) 1
Yes 35 (35.0) 29 (34.1) 0.96 (0.52–1.77)
Endocrine therapy, n (%)
No 65 (65.0) 40 (47.1) 1
Yes 35 (35.0) 45 (52.9) 2.09 (1.16–3.78)*
Outcome: annual drug prescription rate since diagnosis n=95 n=90
Drug prescription rate before diagnosis, n (%)*
≤ Median 80 (84.2) 17 (18.9) 1 1
> Median 15 (15.8) 73 (81.1) 22.90 (10.67–49.14)*** 23.23 (10.14–53.22)***
General practice, n (%)*
Groningen 41 (43.2) 23 (25.6) 1 1
Hoogeveen 21 (22.1) 34 (37.8) 2.89 (1.37–6.09)** 4.09 (1.49–11.24)**
Sappemeer 33 (34.7) 33 (36.7) 1.78 (0.88–3.60) 1.56 (0.60–4.04)
Age at diagnosis, n (%)*
≤ Median 59 (62.1) 34 (37.8) 1 1
> Median 36 (37.9) 56 (62.2) 2.70 (1.49–4.89)** 1.50 (0.66–3.40)
T stage, n (%)
Tis/T1 53 (57.0) 45 (55.6) 1
T2/T3/T4 40 (43.0) 36 (44.4) 1.06 (0.58–1.93)
N stage, n (%)
N0 58 (61.7) 54 (63.5) 1
N+ 36 (38.3) 31 (36.5) 0.92 (0.50–1.70)
Surgery, n (%)
Lumpectomy
a 52 (55.3) 43 (48.9) 1
Mastectomy
b 42 (44.7) 45 (51.1) 1.36 (0.76–2.44)
Chemotherapy, n (%)
712 Support Care Cancer (2012) 20:705–714Dutch GPs is expected to increase because more and more
patients with breast cancer will be treated with endocrine
therapy, including treatment with an aromatase inhibitor
after tamoxifen.
A major strength of the present study is the use of a
primary care database to analyse health care utilisation rates
among women undergoing treatment for breast cancer and
women without breast cancer. As the actual presentation of
health problems was recorded by GPs of the RNG, our
study is much less prone to recall or non-response bias than
surveys with self-reported data on health care use [17].
Moreover, the RNG database made it possible to identify
women with an ICPC code for female breast malignancy
(X76) in their patient record during a specific time period
and to match them with a reference group within the same
population. Although some concerns have been raised
about the validity of the data in primary care databases
[16], the likelihood that the X76 code was valid in the
patient records increased considerably by going back to
participating general practices and examining electronic
records, electronic specialist letters and paper records in
these practices. A matter of concern might be the
completeness or sensitivity of the data in primary care
databases [16, 17]. In the present study, matching was
performed on GP to ensure that inaccuracies in recording
and prescribing were evenly distributed among patients and
women from the reference population. The possibility of
patients diagnosed with breast cancer without the X76 code
in their record [27] cannot be ruled out, as the used data
pertain to those conditions that were brought to the
attention of the GPs and were recorded with ICPC codes
[18]. Record linkage with a local cancer registry might be a
reliable method to verify the completeness of primary care
data [28] given informed consent from patients in both
registries. Another limitation might be the small number of
patients in the present study. As a result, we were not able
to provide a further breakdown of the ICPC diagnostic
categories and to perform regression analysis for count
data. Future studies should involve larger samples of
women with and without breast cancer. Furthermore, our
data apply to a relatively small regional population in the
Netherlands that is influenced by local policies, habits and
health care structures [18]. The GPs who contribute to the
database of the RNG might behave differently from other
GPs in the Netherlands [16], but we have no reasons to
assume this. Therefore, we believe that our results are also
relevant for other primary care contexts [18].
Our study provided insight into the actual role of GPs
during the active breast cancer treatment phase. GPs are
involved in the management of treatment-related side
effects and psychological symptoms, as well as in the
administration of endocrine therapy. Therefore, good
communication across the primary/secondary interface is
important to ensure that they have adequate knowledge of
breast cancer treatments and feel confident in managing
these aspects of their patient’s care [8, 29]. In addition, the
respective roles of GPs and oncologists during active
treatment of patients with breast cancer should be clearly
communicated. A simple guideline might help GPs and
other primary care physicians be more effective when
providing care for patients undergoing breast cancer
treatment [8, 13]. Based on the findings of this study,
interventions across the primary/secondary interface can be
planned to improve quality of life and other outcomes in
patients undergoing breast cancer treatment.
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≤ Median > Median OR (CI) OR (CI)
No 58 (61.1) 63 (70.0) 1
Yes 37 (38.9) 27 (30.0) 0.76 (0.36–1.24)
Endocrine therapy, n (%)
No 59 (62.1) 46 (51.1) 1
Yes 36 (37.9) 44 (48.9) 1.57 (0.87–2.81)
Univariate analysis, odds ratios (OR) and 95% confidence intervals (95% CI) estimated with multivariate logistic regression analysis
Significant at *p<0.05, **p<0.01 and ***p<0.001
aIncluding patients treated with lumpectomy, with and without radiation therapy
bIncluding patients treated with lumpectomy followed by mastectomy, with and without radiation therapy
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